Liminatus Pharma, Inc. Class A Common Stock
LIMN · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Market Cap | $45,103 | $259,808 | $135,594 | $35,443 |
| - Cash | $725 | $1,338 | $0 | $805 |
| + Debt | $1,443 | $1,443 | $0 | $5,122 |
| Enterprise Value | $45,821 | $259,912 | $135,594 | $39,761 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Gross Profit | -$1 | -$1 | $0 | $0 |
| % Margin | – | – | – | – |
| EBITDA | -$1,804 | $176 | -$0 | -$729 |
| % Margin | – | – | – | – |
| Net Income | -$1,823 | $113 | -$0 | -$868 |
| % Margin | – | – | – | – |
| EPS Diluted | -0.068 | 0.005 | -2.55 | -0.12 |
| % Growth | -1,477.6% | 100.2% | -2,025% | – |
| Operating Cash Flow | -$601 | -$8,976 | $0 | -$785 |
| Capital Expenditures | -$13 | $0 | $0 | -$0 |
| Free Cash Flow | -$614 | -$8,976 | $0 | -$786 |